SG11201804148TA - Rsv f protein mutants - Google Patents

Rsv f protein mutants

Info

Publication number
SG11201804148TA
SG11201804148TA SG11201804148TA SG11201804148TA SG11201804148TA SG 11201804148T A SG11201804148T A SG 11201804148TA SG 11201804148T A SG11201804148T A SG 11201804148TA SG 11201804148T A SG11201804148T A SG 11201804148TA SG 11201804148T A SG11201804148T A SG 11201804148TA
Authority
SG
Singapore
Prior art keywords
rsv
rule
international
road
drive
Prior art date
Application number
SG11201804148TA
Inventor
Ye Che
Philip Ralph Dormitzer
Alexey Vyacheslavovich Gribenko
Luke David Handke
Avvari Krishna Prasad
Xiayang Qiu
Mark Edward Ruppen
Xi Song
Kena Anne Swanson
Srinivas Kodali
Xin Xu
KariAnn Sweeney Efferen
Ping Cai
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201804148TA publication Critical patent/SG11201804148TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110101101110111010111101111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/109629 Al 29 June 2017(29.06.2017) WIPO I PCT (51) International Patent Classification: Garnerville, NY 10932 (US). SONG, Xi; 27 Giovanni A61K 39/155 (2006.01) C07K 14/005 (2006.01) Drive, Waterford, CT 06385 (US). SWANSON, Kena A61K 39/12 (2006.01) Anne; 121 East George Avenue, Pearl River, NY 10965 (US). KODALI, Srinivas; 35 Matrick Court, Hillsbor- (21) International Application Number: ough, NJ 08844 (US). XU, Xin; 607 Glasmere Road, Mah- PCT/IB2016/057502 wah, NJ 07430 (US). EFFEREN, KariAnn Sweeney; 43 (22) International Filing Date: Pellom Place, Stamford, CT 06905 (US). CAI, Ping; One 9 December 2016 (09.12.2016) Christie Drive, New City, NY 10956 (US). TOMPKINS, (25) Filing Language: English Kristin Rachael; 6 Morris Road, Garrison, NY 10524 (US). NUNEZ, Lorna Del Pilar; 198 North State Road, (26) Publication Language: English Briarcliff Manor, NY 10510 (US). (30) Priority Data: (74) Agent: WALDRON, Roy F.; PFIZER INC., 235 East 62/387,270 23 December 2015 (23.12.2015) US 42nd Street, MS 235/9/S20, New York, NY 10017 (US). 62/421,184 11 November 2016 (11.11.2016) US (81) Designated States (unless otherwise indicated, for every (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, kind of national protection available): AE, AG, AL, AM, New York, NY 10017 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — (72) Inventors: CHE, Ye; 166 Ledgewood Road, #308, Gro- DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, ton, CT 06340 (US). DORMITZER, Philip Ralph; 10 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, Cobblers Lane, Armonk, NY 10504 (US). GRIBENKO, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, Alexey Vyacheslavovich; 23 Hansen Avenue, New City, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, — NY 10956 (US). HANDKE, Luke David; 144 North NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, Broadway, Nyack, NY 10960 (US). PRASAD, Avvari RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, Krishna; 105 Worsham Drive, Chapel Hill, NC 27516 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (US). QIU, Xiayang; 138 Long Wharf Drive, Mystic, CT ZA, ZM, ZW. 06355 (US). RUPPEN, Mark Edward; 6 Lea Court, [Continued on next page] — = = Title: RSV F PROTEIN MUTANTS (54) = = FIG. = = MELLILKANAITTILTAVITCFASGONITEEFYQSTCSAVSKGYLSALRIGWYTSVITIE = = LSNIKENKONGTDAKVKLIKQELDKYKNAVTELOLLMOSTPATNNRARRELPRFMN = = YTLNNAKKINVILSKKRKRRELGFLLGVGSAIASGVAVSKVLHLEGEVNK KSALLS INKAWSLSNGVSVLTSKVLDLKNYIDKOLLPIVNKOSCSISNIETVIEFOOKNNRLLE = ITREFSVNAGVTTPVSTYMLINSEI [ SLINDMPITNDOKKLMSNNVOIVROOSYSEMS IIKEEVLAYVVOLPLYGVIDTPDVKLFITSPLCTINTKEGSNICLTRIDRGWYCDNAG 1-1 SVSFFPQAEICKVOSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVS SSVITSLGANSCYGKIKOTASNKNRG 1KTFSNGCDYVSNKGVDTVSVGNTLYYVN 0\ V::+ el KOECKSLYVKGEN I NFYDPLVFPSDEFDAS1SQVN EK1 N QS LAFI RKSDELLSA1 GGY 0\ 0 IPEAPRDGOAYVVDGEMLLSTFLGGLVPRGSHHHHHEIGNISHPOFEK 1-1 Elm 1-1 (57) : The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, N compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions. WO 2017/109629 Al MIDEDItitiMIRDEZHEDIONIEHOMMUDIMIE (84) Designated States (unless otherwise indicated, for every as to applicant's entitlement to apply for and be granted kind of regional protection available): ARIPO (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, GH, a patent (Rule 4.170) SZ, RU, — as to the applicant's entitlement to claim the priority of DE, the earlier application (Rule 4.17(iii)) LT, Published: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). SE, GA, — with international search report (Art 21 ( 3 )) — before the expiration of the time limit for amending the Declarations under Rule 4.17: claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — as to the identity of the inventor (Rule 4.17(0) — with sequence listing part of description (Rule 5.2(a))
SG11201804148TA 2015-12-23 2016-12-09 Rsv f protein mutants SG11201804148TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11
PCT/IB2016/057502 WO2017109629A1 (en) 2015-12-23 2016-12-09 Rsv f protein mutants

Publications (1)

Publication Number Publication Date
SG11201804148TA true SG11201804148TA (en) 2018-07-30

Family

ID=57590746

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804148TA SG11201804148TA (en) 2015-12-23 2016-12-09 Rsv f protein mutants
SG10202001389PA SG10202001389PA (en) 2015-12-23 2016-12-09 Rsv f protein mutants

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202001389PA SG10202001389PA (en) 2015-12-23 2016-12-09 Rsv f protein mutants

Country Status (17)

Country Link
US (5) US9950058B2 (en)
EP (1) EP3393512A1 (en)
JP (4) JP6817307B2 (en)
KR (3) KR20230035429A (en)
CN (1) CN108738312A (en)
AU (4) AU2016379097C1 (en)
BR (1) BR112018010805A2 (en)
CA (2) CA2952131C (en)
CO (1) CO2018006301A2 (en)
IL (1) IL260203A (en)
MX (2) MX2018007622A (en)
PE (2) PE20181354A1 (en)
PH (1) PH12018501355A1 (en)
RU (1) RU2723039C2 (en)
SG (2) SG11201804148TA (en)
TW (3) TWI656130B (en)
WO (1) WO2017109629A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN115947873A (en) 2017-04-04 2023-04-11 华盛顿大学 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and uses thereof
KR20200035115A (en) 2017-08-07 2020-04-01 칼더 바이오사이언시스 인코포레이티드 Conformationally stabilized F protein before RSV fusion
CN111655715A (en) 2018-01-29 2020-09-11 默沙东公司 Stabilized RSV F proteins and uses thereof
EP3758747A1 (en) 2018-02-28 2021-01-06 University of Washington Self-asssembling nanostructure vaccines
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CR20210306A (en) * 2018-11-13 2021-07-22 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (en) * 2019-04-25 2021-09-10 北京交通大学 Respiratory syncytial virus pre-fusion F protein and application thereof
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR20220116516A (en) 2019-12-23 2022-08-23 미쓰비시 타나베 파마 코퍼레이션 Mutant RSV F protein and its use
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
CN112899214B (en) * 2020-07-07 2023-08-04 湖南师范大学 Application of waste fish scales in preparation of anisotropic substrate
JP2022023814A (en) 2020-07-27 2022-02-08 ファイザー・インク Purification methods for recombinantly-produced rsv in trimeric form
JP2022023813A (en) 2020-07-27 2022-02-08 ファイザー・インク Improvements to wash solutions for anion exchange chromatography in a method of purification of recombinantly-produced rsv proteins
CN112226444B (en) * 2020-08-25 2022-11-04 北京交通大学 Nucleotide sequence of fusion glycoprotein before full-length fusion of respiratory syncytial virus, recombinant adenovirus vector and application product thereof
JP2022060169A (en) 2020-10-02 2022-04-14 ファイザー・インク Cell culture process for rsv f protein production
CN114685676B (en) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 Recombinant protein, expression method, purification method and application thereof
WO2022175477A1 (en) * 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
JP2024517780A (en) 2021-05-03 2024-04-23 ファイザー・インク Vaccination against bacterial and betacoronavirus infections
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN117715923A (en) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 RSV F protein mutant and application thereof
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
CN116284266B (en) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 Mutant respiratory syncytial virus pre-fusion F protein and application thereof
CN117487823A (en) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 Respiratory syncytial virus mRNA vaccine and preparation method and application thereof
CN117304278B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof
CN117304280B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof
CN117304279B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof
CN117586359A (en) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 Respiratory Syncytial Virus (RSV) polypeptides having immunogenicity
CN117645655A (en) * 2024-01-26 2024-03-05 普大生物科技(泰州)有限公司 Pneumococcal polysaccharide-RSV recombinant protein conjugate vaccine and preparation method thereof
CN117777251A (en) * 2024-02-27 2024-03-29 普大生物科技(泰州)有限公司 RSV nanoparticle vaccine and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec Chimeric antigens
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2164860A2 (en) 2007-06-06 2010-03-24 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP3508505A1 (en) * 2007-12-24 2019-07-10 ID Biomedical Corporation of Quebec Recombinant rsv antigens
BRPI0915960A2 (en) 2008-07-18 2019-09-24 Id Biomedical Corp chimeric respiratory syncytial virus polypeptide antigens
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
HUE051666T2 (en) 2008-12-09 2021-03-29 Novavax Inc Modified rsv f proteins and methods of their use
PL2445526T3 (en) * 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
SG176807A1 (en) * 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
WO2011008974A2 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011043643A1 (en) 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
HUE043879T2 (en) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Rsv immunization regimen
DK3275892T3 (en) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa PRÆFUSIONS-RSV F ANTIGENS
ES2395677B1 (en) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii VRSH F protein in stabilized pre-fusion conformation and specific neutralizing antibodies against it.
CN104080476A (en) 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
SG11201503369RA (en) 2012-11-20 2015-06-29 Glaxosmithkline Biolog Sa Rsv f prefusion trimers
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105188745B (en) 2013-04-25 2019-10-18 扬森疫苗与预防公司 RSV F polypeptide before stabilized soluble fusion
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CN108348593B (en) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 Human Respiratory Syncytial Virus (HRSV) virus-like particle (VLPS) based vaccines
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
EP3393512A1 (en) 2018-10-31
CO2018006301A2 (en) 2018-07-10
TWI756828B (en) 2022-03-01
BR112018010805A2 (en) 2018-11-27
RU2018122823A (en) 2020-01-23
KR20200090932A (en) 2020-07-29
JP2021061845A (en) 2021-04-22
CN108738312A (en) 2018-11-02
US20190125861A1 (en) 2019-05-02
RU2018122823A3 (en) 2020-01-23
US9950058B2 (en) 2018-04-24
AU2019210579B2 (en) 2021-01-28
US20180177864A1 (en) 2018-06-28
MX2018007622A (en) 2018-11-14
JP2023015335A (en) 2023-01-31
AU2021202522A1 (en) 2021-05-27
US10821171B2 (en) 2020-11-03
KR102505354B1 (en) 2023-03-02
TWI656130B (en) 2019-04-11
US20210023200A1 (en) 2021-01-28
US20230218738A1 (en) 2023-07-13
TW202216738A (en) 2022-05-01
PH12018501355A1 (en) 2019-02-18
JP6817307B2 (en) 2021-01-20
KR20230035429A (en) 2023-03-13
TW201920238A (en) 2019-06-01
TWI707866B (en) 2020-10-21
JP7212198B2 (en) 2023-01-24
AU2019210579A1 (en) 2019-08-22
AU2021202522B2 (en) 2023-05-11
TW201726709A (en) 2017-08-01
RU2020115606A (en) 2020-06-29
JP2019511998A (en) 2019-05-09
AU2023214269A1 (en) 2023-10-12
JP2022185022A (en) 2022-12-13
KR20180081614A (en) 2018-07-16
PE20181354A1 (en) 2018-08-22
WO2017109629A1 (en) 2017-06-29
SG10202001389PA (en) 2020-04-29
AU2016379097C1 (en) 2021-04-08
CA3217696A1 (en) 2017-06-23
US20170182151A1 (en) 2017-06-29
IL260203A (en) 2018-07-31
AU2016379097B2 (en) 2019-08-22
CA2952131C (en) 2023-12-05
JP7193522B2 (en) 2022-12-20
AU2016379097A1 (en) 2018-06-07
RU2020115606A3 (en) 2020-11-23
TW202124414A (en) 2021-07-01
RU2723039C2 (en) 2020-06-08
CA2952131A1 (en) 2017-06-23
KR102136678B1 (en) 2020-07-22
MX2021007070A (en) 2021-08-11
US10238732B2 (en) 2019-03-26
PE20232039A1 (en) 2023-12-21
AU2021202522C1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
SG11201804148TA (en) Rsv f protein mutants
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909918XA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201901506VA (en) Distributed systems for the efficient production and use of microbe-based compositions
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201906223TA (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201810605UA (en) Selectively altering microbiota for immune modulation
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201805805VA (en) Recombinogenic nucleic acid strands in situ
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901273TA (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
SG11201810907UA (en) Target reporter constructs and uses thereof
SG11201909837YA (en) Methods for treating lung disorders
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression